We scan new podcasts and send you the top 5 insights daily.
Susanna Banerjee shared that the single-arm Chameleon trial evaluates upfront avutometinib, defactinib, and letrozole to downsize bulky or inoperable disease. Because low-grade serous cancer responds poorly to frontline chemotherapy, targeted shrinking aims to give advanced patients the opportunity to undergo complete surgical resection.
Susanna Banerjee highlighted that the NRG19 trial failed to establish non-inferiority when comparing letrozole monotherapy against standard chemotherapy followed by letrozole. Even though low-grade serous tumors express ER and PR, receptor levels do not predict response, meaning chemotherapy remains necessary.
The landmark GY019 trial confirmed that letrozole alone is inferior to the standard of chemotherapy followed by letrozole maintenance. This was a surprising result for a chemo-resistant tumor, solidifying the need for chemotherapy in the adjuvant setting despite its limited effectiveness.
For BRAF V600E low-grade serous ovarian cancer patients who progress on dabrafenib/trametinib, clinicians can appeal for the KRAS-approved combination avutametinib/defactinib. This strategy is based on evidence of the drug's activity in KRAS wild-type patients, offering a rational off-label option.
The speaker predicts that if the G12D inhibitor and chemotherapy combination proves successful in the metastatic setting, its high response rate and safety profile will make it a compelling option for earlier stages of the disease, such as in neoadjuvant settings for resectable cancers.
In neoadjuvant trials, patients who fail to achieve a pathologic complete response are scientifically invaluable. Their resected tumors, which survived initial treatment, provide critical tissue to study resistance mechanisms. This allows researchers to inform the development of better combination therapies for all stages of disease.
While the avutometanib/defactinib combination is newly approved for KRAS-mutated ovarian cancer, its significant toxicity profile—causing up to a third of patients to stop treatment—creates a clear clinical need for agents like specific KRAS inhibitors that may offer similar efficacy with better tolerability.
In KRAS-mutant low-grade serous ovarian cancer, blocking RAS-RAF-MEK signaling triggers compensatory FAK pathway upregulation as an escape mechanism. Combining the RAF/MEK clamp avutametnib with FAK inhibitor defactinib abrogates this bypass resistance, demonstrating notable activity that recently secured accelerated FDA approval.
Historically, resectability was a static, pre-treatment judgment. With neoadjuvant immunotherapy causing significant tumor and nodal downstaging, surgeons must now dynamically re-evaluate resectability after systemic therapy, expanding surgical options for patients previously deemed inoperable.
While powerful drugs effectively shrink tumors, the response pattern can be a "splatter" rather than a uniform deflation. This creates a significant surgical challenge, making it difficult to define clear margins for breast-conserving surgery and potentially necessitating a more extensive operation despite a good therapeutic response.
The most clinically relevant finding from the NeoAdura trial was not the pathologic response rate, but that giving osimertinib pre-operatively led to more patients successfully undergoing surgery with complete resection, as 8% of patients in the control arm progressed or became unresectable before their operation.